Wolfe Research analyst Andy Chen reiterated a Peerperform rating on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "Limited data but company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE